Eli Lilly is expanding its offerings of its hit weight-loss drug Zepbound for people who want to pay cash instead of using ...
Eli Lilly stock surges past $840, outperforming the S&P 500. Click here to learn why LLY stock is still undervalued and why ...
Eli Lilly and Company (NYSE: LLY) announced the launch of 7.5 mg and 10 mg Zepbound (tirzepatide) single-dose vials, ...
Eli Lilly said on Tuesday it has begun selling higher doses of its popular weight-loss drug Zepbound in vials in the U.S. at ...
1hon MSN
We recently compiled a list of the 20 High Growth Mega Cap Stocks You Can Buy And Hold For Next 5 Years. In this article, we ...
Organovo Holdings, Inc. (Nasdaq:ONVO) (“Organovo” or the “Company”), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel ...
Joe Nadglowski, president and CEO of the Obesity Action Coalition (OAC), appreciated Lilly's efforts to make obesity ...
In this article, we will take a look into Eli Lilly and Co's (NYSE:LLY) DCF analysis, a reliable and data-driven approach to estimating its intrinsic value. Instead of using future free cash flow as ...
Lilly recently revised its revenue forecast for 2024 after seeing weaker-than-expected growth for Zepbound and diabetes brand ...
Eli Lilly said Tuesday that it will offer more doses of its obesity drug Zepbound in vials and lower the prices of the doses ...
Weight-loss drugs aren’t just slimming waists; they create a $100 billion market opportunity. With plenty up for grabs, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results